| Company | Merck |
| Stock Quote | NYSE: MRK |
| Study Name | PREVYMIS (letermovir) |
| Treatment | non-nucleoside CMV inhibitor |
| Status | supplemental New Drug Application (sNDA) Priority Review |
| Catalyst Date | June 5, 2023 |
| Catalyst | PDUFA Date |
| Press Release | Read More |
| Website | Click Here |
| Company | 4D Molecular Therapeutics |
| Stock Quote | NASDAQ: FDMT |
| Study Name | 4D-710 |
| Treatment | Cystic fibrosis lung disease |
| Status | Phase 1/2 |
| Catalyst Date | June 8, 2023 |
| Catalyst | Data Presentation |
| Press Release | Read More |
| Website | Click Here |
| Company | Albireo Pharma |
| Stock Quote | NASDAQ: ALBO |
| Study Name | Bylvay (odevixibat) |
| Treatment | Progressive Familial Intrahepatic Cholestasis (PFIC) |
| Status | supplemental New Drug Application (sNDA) |
| Catalyst Date | June 15, 2023 |
| Catalyst | PDUFA Date |
| Press Release | Read More |
| Website | Click Here |
| Company | argenx |
| Stock Quote | NASDAQ: ARGX |
| Study Name | Efgartigimod (ADAPT-SC) |
| Treatment | Generalized Myasthenia Gravis |
| Status | Phase 3 |
| Catalyst Date | June 20, 2023 |
| Catalyst | PDUFA Date |
| Press Release | Read More |
| Website | Click Here |
| Company | Aldeyra Therapeutics |
| Stock Quote | NASDAQ: ALDX |
| Study Name | ADX-2191 |
| Treatment | Primary vitreoretinal lymphoma (PVRL) |
| Status | New Drug Application (NDA) Priority Review |
| Catalyst Date | June 21, 2023 |
| Catalyst | PDUFA Date |
| Press Release | Read More |
| Website | Click Here |
| Company | Intercept Pharmaceuticals |
| Stock Quote | NASDAQ: ICPT |
| Study Name | Obeticholic Acid (OCA) and Bezafibrate (BZF) |
| Treatment | Primary Biliary Cholangitis (PBC) |
| Status | Phase 3 |
| Catalyst Date | June 22, 2023 |
| Catalyst | PDUFA Date |
| Press Release | Read More |
| Website | Click Here |
| Company | Sarepta Therapeutics |
| Stock Quote | NASDAQ: SRPT |
| Study Name | SRP-9001 |
| Treatment | SRP-9001 (delandistrogene moxeparvovec) |
| Status | Biologics License Applications (BLA) |
| Catalyst Date | June 22, 2023 |
| Catalyst | Data Presentation |
| Press Release | Read More |
| Website | Click Here |
| Company | Bristol-Myers Squibb |
| Stock Quote | NYSE: BMY |
| Study Name | Mavacamten |
| Treatment | symptomatic obstructive hypertrophic cardiomyopathy (oHCM) |
| Status | supplemental New Drug Application (sNDA) |
| Catalyst Date | June 23, 2023 |
| Catalyst | PDUFA Date |
| Website | Click Here |
| Company | Bausch Health |
| Stock Quote | NYSE: BHC |
| Study Name | NOV03 (Perfluorohexyloctane) |
| Treatment | Dry Eye Disease Associated With Meibomian Gland Dysfunction PRN |
| Status | Phase 3 |
| Catalyst Date | June 28, 2023 |
| Catalyst | PDUFA Date |
| Website | Click Here |
| Company | BioCardia |
| Stock Quote | NASDAQ: BCDA |
| Study Name | CardiAMP |
| Treatment | Comprehensive biotherapeutic heart failure solution |
| Status | Data Safety and Monitoring Board (DSMB) Review |
| Catalyst Date | July 12, 2023 |
| Catalyst | Data Presentation |
| Press Release | Read More |
| Website | Click Here |
| Company | Verrica Pharmaceuticals |
| Stock Quote | NASDAQ: VRCA |
| Study Name | VP-102 |
| Treatment | molluscum contagiosum (molluscum) |
| Status | New Drug Application (NDA) |
| Catalyst Date | July 23, 2023 |
| Catalyst | PDUFA Date |
| Press Release | Read More |
| Website | Click Here |
| Company | Biogen |
| Stock Quote | NASDAQ: BIIB |
| Study Name | Zuranolone |
| Treatment | Major depressive disorder (MDD) and Postpartum depression (PPD) |
| Status | Phase 2 |
| Catalyst Date | August 5, 2023 |
| Catalyst | PDUFA Date |
| Press Release | Read More |
| Website | Click Here |
| Company | Neurocrine Biosciences |
| Stock Quote | NASDAQ: NBIX |
| Study Name | Valbenazine (KINECT-HD) |
| Treatment | Chorea in Huntington Disease |
| Status | supplemental New Drug Application (sNDA) |
| Catalyst Date | August 20, 2023 |
| Catalyst | PDUFA Date |
| Press Release | Read More |
| Website | Click Here |
| Company | SpringWorks Therapeutics |
| Stock Quote | NASDAQ: SWTX |
| Study Name | Nirogacestat |
| Treatment | Ovarian Granulosa Cell Tumors |
| Status | New Drug Application (NDA) Priority Review |
| Catalyst Date | August 27, 2023 |
| Catalyst | PDUFA Date |
| Press Release | Read More |
| Website | Click Here |
| Company | SpringWorks Therapeutics |
| Stock Quote | NASDAQ: SWTX |
| Study Name | Nirogacestat (DeFi) |
| Treatment | Desmoid tumors |
| Status | New Drug Application (NDA) |
| Catalyst Date | August 27, 2023 |
| Catalyst | PDUFA Date |
| Press Release | Read More |
| Website | Click Here |
| Company | Ocuphire Pharma |
| Stock Quote | NASDAQ: OCUP |
| Study Name | Nyxol |
| Treatment | reversal of pharmacologically induced mydriasis (dilation of pupil for eye exams) |
| Status | Phase 3 |
| Catalyst Date | September 28, 2023 |
| Catalyst | PDUFA Date |
| Press Release | Read More |
| Website | Click Here |
| Company | Alnylam Pharmaceuticals |
| Stock Quote | NASDAQ: ALNY |
| Study Name | Patisiran (APOLLO-B) |
| Treatment | Cardiomyopathy of both hereditary and wild-type ATTR amyloidosis |
| Status | supplemental New Drug Application (sNDA) |
| Catalyst Date | October 8, 2023 |
| Catalyst | PDUFA Date |
| Press Release | Read More |
| Website | Click Here |
| Company | Bristol-Myers Squibb |
| Stock Quote | NYSE: BMY |
| Study Name | Opdivo (nivolumab) |
| Treatment | resected esophageal or gastroesophageal junction (GEJ) cancer in the adjuvant setting |
| Status | supplemental Biologics License Applications (sBLA) |
| Catalyst Date | October 13, 2023 |
| Catalyst | PDUFA Date |
| Press Release | Read More |
| Website | Click Here |
| Company | Ardelyx |
| Stock Quote | NASDAQ: ARDX |
| Study Name | tenapanor |
| Treatment | control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis |
| Status | New Drug Application (NDA) |
| Catalyst Date | October 17, 2023 |
| Catalyst | PDUFA Date |
| Press Release | Read More |
| Website | Click Here |
| Company | Bausch Health |
| Stock Quote | NYSE: BHC |
| Study Name | IDP-126 |
| Treatment | Acne vulgaris in patients nine years of age and older |
| Status | New Drug Application (NDA) |
| Catalyst Date | October 20, 2023 |
| Catalyst | PDUFA Date |
| Press Release | Read More |
| Website | Click Here |
| Company | Regeneron Pharmaceuticals |
| Stock Quote | NASDAQ: REGN |
| Study Name | Dupixent (dupilumab) |
| Treatment | moderate-to-severe asthma |
| Status | supplemental Biologics License Applications (sBLA) Priority Review |
| Catalyst Date | October 22, 2023 |
| Catalyst | PDUFA Date |
| Website | Click Here |
| Company | Pacira BioSciences |
| Stock Quote | NASDAQ: PCRX |
| Study Name | EXPAREL (Bupivacaine Liposome Injectable Suspension) |
| Treatment | Postsurgical Analgesia in Children |
| Status | New Drug Application (NDA) |
| Catalyst Date | November 13, 2023 |
| Catalyst | PDUFA Date |
| Press Release | Read More |
| Website | Click Here |
| Company | Aldeyra Therapeutics |
| Stock Quote | NASDAQ: ALDX |
| Study Name | Reproxalap |
| Treatment | Small-molecule modulator of RASP |
| Status | New Drug Application (NDA) |
| Catalyst Date | November 23, 2023 |
| Catalyst | PDUFA Date |
| Press Release | Read More |
| Website | Click Here |
| Company | Ionis Pharmaceuticals |
| Stock Quote | NASDAQ: IONS |
| Study Name | Eplontersen (formerly AKCEA-TTR-L) |
| Treatment | Hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN) |
| Status | New Drug Application (NDA) Priority Review |
| Catalyst Date | December 22, 2023 |
| Catalyst | PDUFA Date |
| Press Release | Read More |
| Website | Click Here |
| Company | Checkpoint Therapeutics |
| Stock Quote | NASDAQ: CKPT |
| Study Name | Cosibelimab (cSCC) |
| Treatment | Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC) |
| Status | Biologics License Applications (BLA) |
| Catalyst Date | January 3, 2024 |
| Catalyst | PDUFA Date |
| Press Release | Read More |
| Website | Click Here |
| Company | Minerva Neurosciences |
| Stock Quote | NASDAQ: NERV |
| Study Name | Roluperidone (MIN-101) |
| Treatment | Schizophrenia |
| Status | New Drug Application (NDA) |
| Catalyst Date | February 26, 2024 |
| Catalyst | PDUFA Date |
| Press Release | Read More |
| Website | Click Here |
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MORE